Context Therapeutics (CNTX) Free Cash Flow (2020 - 2026)

Context Therapeutics has disclosed Free Cash Flow across 7 years of filings, most recently posting -$11.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$11.5 million, down 126.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 115.02% YoY), and the FY2025 annual result was -$26.4 million, down 81.4% from the prior year.
• Free Cash Flow came in at -$11.5 million for Q1 2026 at Context Therapeutics, down from -$8.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.9 million in Q3 2024 to a low of -$11.5 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$4.6 million (2023), against an average of -$5.1 million.
• Across the five-year window, Free Cash Flow sank 6762.0% in 2022 and jumped 43.93% in 2024, its largest moves.
• Context Therapeutics' Free Cash Flow stood at -$3.9 million in 2022, then sank by 83.91% to -$7.2 million in 2023, then jumped by 32.11% to -$4.9 million in 2024, then plunged by 82.26% to -$8.9 million in 2025, then slipped by 28.22% to -$11.5 million in 2026.
• The last three Free Cash Flow figures came in at -$11.5 million (Q1 2026), -$8.9 million (Q4 2025), and -$6.6 million (Q3 2025), per Business Quant data.